Apothecary Pharma, LLC, Cary, NC

Is Apothecary Pharma, LLC an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Apothecary Pharma, LLC in Cary, NC, first registered Sep 7, 2024 and most recently registered Oct 21, 2026. FDA lists its last inspection as Sep 2, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Cary, NC
Initial registration
Sep 7, 2024
Most recent registration
Oct 21, 2026
Last inspection
Sep 2, 2026
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Open
Intends to compound sterile drugs from bulk substances
Yes
Earlier inspections
FDA notes that an earlier inspection led to a Form 483, warning letter or other action

FDA inspections and actions on record

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Apothecary Pharma LLC, Cary, NC, a 503B facility, with 2 listed actions, including 1 Form 483 and 1 warning letter (2025).

Document
Dec 1, 2025Warning letterWarning Letter Issued 12/01/2025fda.gov
May 15, 2025Form 483483 Issued 05/15/2025fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Apothecary Pharma LLC, Cary, NC (FEI number 3032314463), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
May 15, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30323144631269678

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 8 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 12, 2025 to May 15, 2025: 8 observations

Firm on the cover
Apothecary Pharma LLC, 1913 Evans Rd, Cary, NC 27513-20 41
FEI number
3032314463
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
60 Eighth Street NE Atlanta, GA 30309
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically, the QCU failed to

-ensure all batch records are reviewed for completeness -review Certification Report Control ID #4049-339748-64877 (dated 11/25/2024) for the ISO 7 filling clean room and Certification Report 5041-1698657R2 (dated 11/25/2024) for the ISO 5 laminar air flow work station before producing sterile drug products that were distributed to market in 2025 -finalize all draft procedures including: SOP1002 Responsibilities of Apothecaiy's Quality Unit, SOPl0l l Corrective Action/ Preventative Action (CAPA), SOP1012 Batch Records, and SOP1014 Out-Of-Specification (OOS) Results -follow SOP2004 Visual Inspection bv shaking and inventing the vials too forcibly generating excessive air bubbles. SOP 2004 states to <Redacted B4> avoiding air bubble formation.

Observation 2

Protective apparel is not worn as necessary to protect drug products from contamination.

Specifically, on 5/12/2025, during production of Semaglutide Injection 2.5mg/mL Batch <Redacted B4> we observed

-Operators had exposed skin of forehead and cheeks

-SOP0003 Cleanroom Entity and Exit is not followed. For example, operators did not don shoe covers over facility clogs. Per the SOP the coverall should be donned prior to booties, however, we observed the booties donned before the coverall. An operator entered the gowning room with goggles on instead of donning goggles in the gowning room. An operator entered the gowning room with a mask instead of donning the mask in the gowning room. Also, the operators ignored the line of demarcation. We observed one operator gowned on the duty side of the line of demarcation. We observed another operator wear the face mask upside down.

Facility and Buildings Control System

Observation 3

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to contJ.·ol the aseptic conditions.

Specifically, on 5/12/2025, during production of Semaglutide Injection 2.5mg/mL Batch <Redacted B4> we observed the ISO 5 LFH appears to have rust on the outside wall, underneath the bench, and on top panel. Additionally, the top panel of the ISO 5 LFH appeared to be dented and damaged.

Observation 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, on 5/12/2025, during production of Semaglutide Injection 2.5mg/mL Batch <Redacted B4> we observed operator(s)

-push down the trash into the bag with their gloved hand and then returned to the ISO 5 without disinfecting their gloves

-fail to consistently disinfect items, including the air particulate counter and bag of sterile wipes, before putting them into the ISO 5 hood.

Production Control System

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically, smoke studies have not been performed under dynamic conditions to support the production and release of <Redacted B4> batches of Tirzepatide l0mg/mL. Additionally, we observed the volume and/or location of the smoke in the 11/25/2024 smoke study video for the filling room and ISO 5 LFH appeared insufficient to visualize the airflow pattern.

Observation 6

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, on 5/12/2025, during production of Semaglutide Injection 2.5mg/mL Batch <Redacted B4>

a.) we observed operator(s)

-block first air by putting their gloved hands and wrists over opened vials during filling

-fail to move with slow and deliberate movements during filling

-rest their forearms on the ISO 5 bench during filling

-lean their heads and upper body into the hood exposing skin, from cheeks and forehead.

b.) vials behind the first row of vials were blocked from first air in the ISO 5 <Redacted B4> Ilaminar flow hood.

Observation 7

Batch production and control records do not include in-process and laboratory control results for each batch of drug product produced.

Specifically, your visual inspection program for the implementation and documentation of in-process controls, tests, and examinations is inadequate. For example, the batch records for Tirzepatide 10 mg/mL

-Batch <Redacted B4> states that 12 vials were rejected out of <Redacted B4> that were inspected.

-Batch <Redacted B4> states that 11 vials were rejected out of <Redacted B4> that were inspected.

-Batch <Redacted B4> states that 13 vials were rejected out of <Redacted B4> that were inspected.

The batch records do not specify whether rejects were due to critical, major, or minor defects or whether the acceptance criteria for visual inspection defects were met. You did not document complete results of 100% visual inspection, including specification of identified rejects. You did not document results of Acceptance Quality Limit (AQL) inspection completed after 100% visual inspection.

503B

Observation 8

Your outsourcing facility has not submitted a report to FDA identifying a product compounded during the previous six months as required by section 503B(b )(2)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Specifically, your outsourcing facility failed to submit an initial product report to the FDA upon registration as a 503B outsourcing facility.

registration as a 503B outsourcing facility.

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."

GLP-1 records in this index

The same legal name appears in 1 GLP-1 warning letter and 1 GLP-1 recall report in this index. See the Apothecary Pharma LLC record page.

Later letters FDA listsLetter
Dec 1, 2025Compounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

Record
Sep 24, 2026Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC 27513, NDC 85091-001-18.Lack of Assurance of SterilityClass IIOngoingD-0036-2027

The Apothecary Pharma, LLC pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 5 products naming tirzepatide under the labeler name “Apothecary Pharma LLC”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (5). The compounded product reports cover FDA reporting periods 2026-1 to 2026-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
85091-001TirzepatideTirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS18 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1Compounded drugs
85091-003TirzepatideTirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS9 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1Compounded drugs
85091-004Tirzepatide and B12Tirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS17 mg/1 mL; 1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1Compounded drugs
85091-005Tirzepatide and B12Tirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS8.5 mg/1 mL; 1 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1Compounded drugs
85091-006Tirzepatide and GlycineTirzepatide InjectionINJECTION, SOLUTIONSUBCUTANEOUS17 mg/1 mL; 5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2026-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.